A Phase I Trial of Imatinib Mesylate (Gleevec, Formerly Known as STI571) in Combination With Daunorubicin and Cytarabine for C-Kit Positive Relapsed AML.
Phase of Trial: Phase I
Latest Information Update: 14 Feb 2013
At a glance
- Drugs Imatinib (Primary) ; Cytarabine; Daunorubicin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 01 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jan 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 17 Nov 2006 New trial record.